New research has uncovered immune changes in cancer patients that could help identify which patients are most at risk of ...

Patients with history of preeclampsia have increased risk for myocardial infarction and worse myocardial infarction outcomes.

Some cancers and chronic inflammatory diseases are treated with immunotherapies. These stimulate the patient's immune system ...

Inflammatory processes have been identified as key mediators of the deleterious effects of ischemia/reperfusion in ST-segment–elevation myocardial infarction ... was performed on a 1.5T Siemens ...

gHeart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, and Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain ...

Department of Anesthesiology, The First Affiliated Hospital of Chongqing Medical University, No 1. Youyi Road, Yuzhong District, Chongqing 400016, China The Chongqing Key Laboratory of Translational ...

Objective Compare survival in patients with ST-elevation myocardial infarction (STEMI) treated with a pharmacoinvasive (PI) or primary percutaneous coronary intervention (pPCI) strategy based on ...

Objective To evaluate the risk of stroke and myocardial infarction (MI) in adult patients with systemic lupus erythematosus (SLE) through a systematic review and meta-analysis. Methods We searched ...

Background: Deng's Yangxin Decoction (DYX) is a Chinese herbal formula used in clinical practice to treat patients with myocardial infarction (MI ... This analysis underscores the immune system's ...

Non-ST-segment elevation myocardial infarction (NSTEMI) is the most common acute coronary syndrome diagnosis in older patients. In the UK, there are ~20 000 NSTEMI cases annually in patients aged ≥75 ...

Background: Mitochondrial metabolism and immune inflammation play pivotal roles in the MI pathogenesis of myocardial infarction (MI); however ... geometry and function using the Silicon Wave 30 system ...